Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Eric Jonasch, MD
CONTACT
Lead
M.D. Anderson Cancer Center
With
Primary Objective: 1\. A composite primary endpoint of objective response rate (ORR) or pathologic response rate (PRR) at 12 weeks after neoadjuvant therapy. objective response - defined as partial \[≥ 30% decrease in largest diameter\] or complete response on imaging at 12 weeks after neoadjuvant therapy (according to Response Evaluation Criteria In Solid Tumors \[RECIST\] criteria) (Appendix 14.2) Pathologic response - defined as ≤25% residual viable tumor in post-therapy pathology specimen. Secondary Objectives: 1. Relapse-Free Survival (RFS) - defined as the length of time after randomization to date of radiographic/clinical progression, recurrence or death 2. Safety/Tolerability - including adverse events \[by National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE)\], laboratory results, vital signs, physical examinations 3. Quality of Life - as measured by patient-reported outcome measures, including EORTC-QLQ-C30 and FACT-G Single Item GP5 (Appendix 14.3, Appendix 14.4)
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
